PET imaging of cerebral perfusion and oxygen consumption in acute ischemic stroke: Relation to outcome
The authors used positron emission tomography (PET) to assess the relation between combined imaging of cerebral blood flow and oxygen consumption 5-18 h after first middle cerebral artery (MCA) stroke and neurological outcome at 2 months. All 18 patients could be classified into three visually defined PET patterns of perfusion and oxygen consumption changes. Pattern 1 suggested extensive irreversible damage and was consistently associated with poor outcome. Pattern 2 suggested continuing ischemia and was associated with variable outcome. Pattern 3 with hyperperfusion and little or no metabolic alteration, was associated with excellent recovery, which suggests that early reperfusion is beneficial. This relation between PET and outcome was highly significant. The results suggest that within 5-18 h of stroke onset, PET is a good predictor of outcome in patterns 1 and 3, for which therapy seems limited. The absence of predictive value for pattern 2 suggests that it is due to a reversible ischemic state that is possibly amenable to therapy. These findings may have important implications for acute MCA stroke management and for patients' selection for therapeutic trials.
- OSTI ID:
- 6147821
- Journal Information:
- Lancet; (United States), Vol. 341:8850; ISSN 0099-5355
- Country of Publication:
- United States
- Language:
- English
Similar Records
Procedural Predictors of Outcome in Patients Undergoing Endovascular Therapy for Acute Ischemic Stroke
Baicalin attenuates focal cerebral ischemic reperfusion injury through inhibition of nuclear factor {kappa}B p65 activation
Related Subjects
BRAIN
POSITRON COMPUTED TOMOGRAPHY
ISCHEMIA
DIAGNOSIS
BLOOD FLOW
OXYGEN
PATIENTS
PERFUSED ORGANS
ANEMIAS
BODY
CARDIOVASCULAR DISEASES
CENTRAL NERVOUS SYSTEM
COMPUTERIZED TOMOGRAPHY
DIAGNOSTIC TECHNIQUES
DISEASES
ELEMENTS
EMISSION COMPUTED TOMOGRAPHY
HEMIC DISEASES
NERVOUS SYSTEM
NONMETALS
ORGANS
SYMPTOMS
TOMOGRAPHY
VASCULAR DISEASES
550601* - Medicine- Unsealed Radionuclides in Diagnostics